The first randomized clinical trial of an antidepressant in patients who had anxiety disorder and a depression episode reported today that it could reduce anxiety symptomatology.
The trial was led by researchers at Columbia University and showed that an antidepressant was effective in treating anxiety symptoms among a group of patients with major depressive disorder.
“We were surprised by how well it worked,” said lead author Michael Fuchs, MD, PhD, professor of psychiatry at Columbia and the director of the NYU Anxiety Disorders Center.
“We were looking for an antidepressant that would work for this group of people.”
Fuchs and his colleagues enrolled 51 adults with anxiety disorders in the study.
They received an initial dose of a combination of fluoxetine (Zoloft), clomipramine (Luvox), or haloperidol (Zohydro) along with a placebo.
The study participants were randomly assigned to receive either a 10 mg dose of fluoride (ZF) or a placebo for six weeks.
During the study, the researchers recorded participants’ anxiety symptoms, and patients who were in the treatment group reported fewer anxiety symptoms.
After six weeks, the patients were randomized to either the fluoxethide group or the placebo group.
The fluoxeticide group also received fluoxedronate (Xanax) along and was randomly assigned either to a behavioral therapy session or a cognitive behavioral therapy group.
At six months, the fluozetine group reported significantly fewer anxiety symptom scores, and the cognitive behavioral treatment group also reported significantly less anxiety symptoms than did the fluooxetinaic group.
The findings were published today in the journal Psychological Medicine.
Fuchs noted that this was a small study and did not show that the fluoridacarbonyl monofluoride antidepressant, fluoxecin, would reduce anxiety in the short term.
He noted that more studies are needed to determine if the treatment can work in a longer-term setting, such as in people with major depression, to see if it is effective.
The next step will be to continue to test the fluoroquinolones and see how well they affect the long-term treatment of anxiety, Fuchs said.